Ketamine for pain: big study launches to see if it really works

NCT ID NCT07648771

Not yet recruiting Knowledge-focused Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 800 people who are already scheduled to receive ketamine infusions for chronic pain as part of their regular care. Researchers will use surveys to track pain levels, opioid use, and overall well-being for up to 16 weeks. A comparison group includes patients who were recommended ketamine but denied insurance coverage. The goal is to understand how well ketamine works in the real world and how insurance denials impact patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ketamine (intravenous infusion)
What this could lead to: If successful, this study could provide real-world evidence on how well ketamine works for chronic pain and how insurance denials affect patients.
What could go wrong: This is an observational registry, not a controlled trial. Results may be influenced by patient selection and lack of blinding. It cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia Chronic Pain chronic pain syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC PAIN KETAMINE

Contacts and locations

Locations

Stanford Health Care

Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.